ADMA Biologics (ADMA) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Vera Therapeutics (VERA) has outperformed ADMA Biologics (ADMA) over the past year, losing 1.8% versus a loss of 27.5%. Over five years, ADMA leads with a +821.8% price change compared with +101.5% for VERA. ADMA Biologics is the larger company by market cap ($2.27 billion vs $2.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADMA | VERA |
|---|---|---|
| Share price | $10.14 | $30.25 |
| Market cap | $2.27B | $2.18B |
| 1-day change | -0.39% | +2.82% |
| YTD return | -44.41% | -40.26% |
| 1-year return | -27.52% | -1.79% |
| 5-year return | +821.82% | +101.53% |
| P/E ratio (TTM) | 14.49 | — |
| Forward P/E | 10.75 | — |
| EPS (TTM) | $0.70 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.46 | $56.05 |
| 52-week low | $7.21 | $23.05 |
| Distance from 52-week high | -50.44% | -46.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +67.65% | +156.20% |
| Average volume | 2.62M | 2.24M |
| Shares outstanding | 223.98M | 72.06M |
| Employees | 640 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VERA has outperformed ADMA by 25.7 percentage points over the past year.
About ADMA Biologics
ADMA stock →ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 640 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
ADMA vs VERA FAQ
Which is bigger, ADMA Biologics or Vera Therapeutics?
ADMA Biologics (ADMA) is larger, with a market capitalization of $2.27B compared with $2.18B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, ADMA or VERA?
VERA returned -1.79% over the past 12 months, compared with -27.52% for ADMA (price return, excluding dividends). Past performance does not predict future results.
Are ADMA Biologics and Vera Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for ADMA Biologics and Biotechnology: Pharmaceutical Preparations for Vera Therapeutics.